KR20230173731A - 1가 항-프로페르딘 항체 및 항체 단편 - Google Patents

1가 항-프로페르딘 항체 및 항체 단편 Download PDF

Info

Publication number
KR20230173731A
KR20230173731A KR1020237042534A KR20237042534A KR20230173731A KR 20230173731 A KR20230173731 A KR 20230173731A KR 1020237042534 A KR1020237042534 A KR 1020237042534A KR 20237042534 A KR20237042534 A KR 20237042534A KR 20230173731 A KR20230173731 A KR 20230173731A
Authority
KR
South Korea
Prior art keywords
gly
ser
ala
val
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020237042534A
Other languages
English (en)
Korean (ko)
Inventor
더글라스 엘. 쉐리단
폴 피. 탐부리니
타네이샤 앤-타나라 맥
월터 씨. 뵈그틀리
Original Assignee
알렉시온 파마슈티칼스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알렉시온 파마슈티칼스, 인코포레이티드 filed Critical 알렉시온 파마슈티칼스, 인코포레이티드
Publication of KR20230173731A publication Critical patent/KR20230173731A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020237042534A 2017-01-30 2018-01-30 1가 항-프로페르딘 항체 및 항체 단편 Ceased KR20230173731A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762452187P 2017-01-30 2017-01-30
US62/452,187 2017-01-30
KR1020197021910A KR102613874B1 (ko) 2017-01-30 2018-01-30 1가 항-프로페르딘 항체 및 항체 단편
PCT/US2018/015985 WO2018140956A1 (en) 2017-01-30 2018-01-30 Monovalent anti-properdin antibodies and antibody fragments

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197021910A Division KR102613874B1 (ko) 2017-01-30 2018-01-30 1가 항-프로페르딘 항체 및 항체 단편

Publications (1)

Publication Number Publication Date
KR20230173731A true KR20230173731A (ko) 2023-12-27

Family

ID=62978808

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020237042534A Ceased KR20230173731A (ko) 2017-01-30 2018-01-30 1가 항-프로페르딘 항체 및 항체 단편
KR1020197021910A Active KR102613874B1 (ko) 2017-01-30 2018-01-30 1가 항-프로페르딘 항체 및 항체 단편

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020197021910A Active KR102613874B1 (ko) 2017-01-30 2018-01-30 1가 항-프로페르딘 항체 및 항체 단편

Country Status (12)

Country Link
US (1) US11198725B2 (enExample)
EP (1) EP3573661A4 (enExample)
JP (3) JP7101684B2 (enExample)
KR (2) KR20230173731A (enExample)
CN (2) CN118184777A (enExample)
AU (2) AU2018212012B2 (enExample)
BR (1) BR112019014652A2 (enExample)
CA (1) CA3049806A1 (enExample)
CO (1) CO2019007686A2 (enExample)
IL (2) IL309890A (enExample)
MX (3) MX2019008827A (enExample)
WO (1) WO2018140956A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019028269A2 (pt) 2017-07-11 2020-07-14 Alexion Pharmaceuticals, Inc. polipeptídeos que se ligam ao componente c5 do complemento ou à albumina sérica e suas proteínas de fusão
ES2974200T3 (es) * 2018-09-13 2024-06-26 Regeneron Pharma Rata nuligénica para el gen del factor H del complemento como modelo de glomerulopatía C3
WO2021140475A1 (en) * 2020-01-08 2021-07-15 Cadila Healthcare Limited Anti-properdin antibodies and preparation thereof
CN116437913A (zh) 2020-09-23 2023-07-14 艾其林医药公司 用于治疗补体介导的病症的药物化合物
WO2022089576A1 (zh) * 2020-10-30 2022-05-05 广州市妇女儿童医疗中心 用于抑制mhc-i和/或ii信号通路的试剂在治疗胆道闭锁中的应用
WO2023023227A1 (en) 2021-08-20 2023-02-23 Alexion Pharmaceuticals, Inc. Methods for treating sickle cell disease or beta thalassemia using complement alternative pathway inhibitors
US11981727B2 (en) 2021-08-31 2024-05-14 Novelmed Therapeutics, Inc Monospecific and bispecific antibodies and antigen binding fragments thereof
WO2024108529A1 (en) * 2022-11-25 2024-05-30 Linno Pharmaceuticals Inc. Properdin binding protein and use thereof
CA3264087A1 (en) * 2022-08-05 2024-02-08 Alexion Pharma Inc Pharmaceutical compositions based on fusion proteins and their methods of use
WO2024049951A1 (en) * 2022-08-31 2024-03-07 Alexion Pharmaceuticals, Inc. Dosage and administration of fusion polypeptides for treatment of sickle cell disease
KR20250112858A (ko) 2022-11-25 2025-07-24 리노 파마슈티컬스 아이엔씨. 프로퍼딘 결합 단백질 및 이의 용도
CN120399074A (zh) * 2023-06-02 2025-08-01 安徽金百奥生物科技有限公司 一种与人dr3胞外域高亲和力的纳米抗体

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1272647T3 (en) 2000-04-11 2014-12-15 Genentech Inc Multivalent antibodies and uses thereof
US7423128B2 (en) * 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
JP5735194B2 (ja) 2005-01-25 2015-06-17 セル セラピューティクス インコーポレーテッド 改善された生体内半減期を有する生物学的に活性なタンパク質
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
ES2551202T5 (es) * 2005-11-04 2018-11-30 Genentech, Inc. Uso de inhibidores de la vía del complemento para tratar enfermedades oculares
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
WO2011112850A2 (en) * 2010-03-10 2011-09-15 Novelmed Therapeutics, Inc. Humanized and chimeric anti-properdin antibodies
ES2538114T3 (es) * 2008-03-03 2015-06-17 Novelmed Therapeutics, Inc. Anticuerpos anti-properdina
NZ597259A (en) 2009-06-23 2014-04-30 Alexion Pharma Inc Bispecific antibodies that bind to complement proteins
US20110172398A1 (en) * 2009-10-02 2011-07-14 Boehringer Ingelheim International Gmbh Bispecific binding molecules for anti-angiogenesis therapy
EA024507B1 (ru) * 2010-09-28 2016-09-30 Амилин Фармасьютикалс, Ллк Хорошо растворимые лептины
KR101650995B1 (ko) * 2010-11-08 2016-08-25 노파르티스 아게 Ｃｘｃｒ２ 결합 폴리펩티드
WO2013006449A2 (en) * 2011-07-01 2013-01-10 The Trustees Of The University Of Pennsylvania Anti-properdin antibodies and uses thereof
CN104271588B (zh) * 2011-07-08 2017-10-10 安米林药品有限责任公司 具有增强的作用持续时间和降低的免疫原性的工程改造的多肽
CA2859493A1 (en) 2011-12-21 2013-06-27 Novartis Ag Compositions and methods for antibodies targeting factor p
CA2862448A1 (en) * 2011-12-28 2013-07-04 Novelmed Therapeutics, Inc. Aglycosylated human antibody and fusion protein and uses thereof
AU2013326932B2 (en) 2012-10-04 2019-06-06 Novelmed Therapeutics, Inc. Alternative pathway specific antibodies for treating hemolytic diseases
NL2013661B1 (en) * 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
CN110003335B (zh) * 2019-04-12 2023-07-04 深圳普瑞金生物药业股份有限公司 Cd47单域抗体、核酸及试剂盒

Also Published As

Publication number Publication date
AU2018212012B2 (en) 2025-02-13
EP3573661A1 (en) 2019-12-04
CO2019007686A2 (es) 2019-07-31
WO2018140956A1 (en) 2018-08-02
KR20190111946A (ko) 2019-10-02
US20220162292A1 (en) 2022-05-26
US20190352381A1 (en) 2019-11-21
CA3049806A1 (en) 2018-08-02
CN110831626B (zh) 2024-04-19
IL309890A (en) 2024-03-01
JP2022153405A (ja) 2022-10-12
CN118184777A (zh) 2024-06-14
JP2024116321A (ja) 2024-08-27
JP7101684B2 (ja) 2022-07-15
CN110831626A (zh) 2020-02-21
MX2023007840A (es) 2023-07-07
IL267898B1 (en) 2024-02-01
RU2019124873A (ru) 2021-03-01
IL267898A (en) 2019-09-26
MX2019008827A (es) 2019-09-26
MX2023004333A (es) 2023-05-04
BR112019014652A2 (pt) 2020-08-18
AU2018212012A1 (en) 2019-07-25
JP2020507561A (ja) 2020-03-12
EP3573661A4 (en) 2020-08-12
KR102613874B1 (ko) 2023-12-15
RU2019124873A3 (enExample) 2021-03-01
US11198725B2 (en) 2021-12-14
IL267898B2 (en) 2024-06-01
AU2025200709A1 (en) 2025-02-20

Similar Documents

Publication Publication Date Title
KR102613874B1 (ko) 1가 항-프로페르딘 항체 및 항체 단편
US11286312B2 (en) Multispecific antibodies
JP6608702B2 (ja) 補体関連疾患の予防及び治療のためのｃ５抗体及び方法
US20250163138A1 (en) Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof
US20240024520A1 (en) Autonomous knob domain peptides
US12497445B2 (en) Monovalent anti-properdin antibodies and antibody fragments
RU2790103C2 (ru) Моновалентные антитела к пропердину и фрагменты антител
HK40024594A (en) Monovalent anti-properdin antibodies and antibody fragments
HK40024594B (zh) 单价抗备解素抗体及抗体片段
WO2024108529A1 (en) Properdin binding protein and use thereof
WO2023034842A2 (en) Monospecific and bispecific antibodies and antigen binding fragments thereof
HK40027205A (en) Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601